TI
NTLA icon

Trexquant Investment’s Intellia Therapeutics NTLA Stock Holding History

Trexquant Investment’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.05M Buy
+298,174
New +$4.17M 0.03% 741
2025
Q4 		– Sell
-270,115
Closed -$4.66M – 1826
2025
Q3 		$4.66M Sell
270,115
-857,216
-76% -$10.6M 0.05% 575
2025
Q2 		$10.6M Buy
1,127,331
+522,635
+86% +$4.29M 0.12% 228
2025
Q1 		$4.3M Sell
604,696
-62,936
-9% -$636K 0.05% 570
2024
Q4 		$7.78M Buy
+667,632
New +$10.4M 0.09% 360
2024
Q3 		– Sell
-170,828
Closed -$3.82M – 1767
2024
Q2 		$3.82M Buy
+170,828
New +$4.07M 0.06% 492
2022
Q4 		– Sell
-26,551
Closed -$1.49M – 1622
2022
Q3 		$1.49M Buy
+26,551
New +$1.65M 0.05% 420
2021
Q4 		– Sell
-11,596
Closed -$1.56M – 1527
2021
Q3 		$1.56M Buy
+11,596
New +$1.76M 0.12% 233
2021
Q2 		– Sell
-12,493
Closed -$1M – 1372
2021
Q1 		$1M Buy
+12,493
New +$839K 0.09% 283
2020
Q4 		– Sell
-44,753
Closed -$890K – 1352
2020
Q3 		$890K Buy
44,753
+9,871
+28% +$206K 0.06% 460
2020
Q2 		$733K Buy
34,882
+9,381
+37% +$159K 0.05% 518
2020
Q1 		$312K Buy
25,501
+10,561
+71% +$142K 0.02% 839
2019
Q4 		$219K Buy
14,940
+2,490
+20% +$34.6K 0.01% 877
2019
Q3 		$166K Buy
12,450
+1,093
+10% +$17.4K 0.01% 775
2019
Q2 		$186K Buy
+11,357
New +$179K 0.02% 697
2018
Q3 		– Sell
-20,301
Closed -$555K – 1119
2018
Q2 		$555K Buy
+20,301
New +$492K 0.04% 506

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Trexquant Investment's NTLA Position: Q2 2026 in Review

Trexquant Investment opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 298,174 shares worth $5.05M. The stake represents 0.03% of the portfolio and ranks #741 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in NTLA as recently as Q3 2025.

Trexquant Investment first reported a position in NTLA in Q2 2018 and has held it in 16 quarters since. The position peaked at $10.6M in Q2 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Trexquant Investment held 298,174 shares of Intellia Therapeutics worth $5.05M as of Q2 2026.
  • Intellia Therapeutics was a new Trexquant Investment position in Q2 2026.
  • Intellia Therapeutics made up 0.03% of Trexquant Investment's portfolio in Q2 2026, its #741 holding.
  • Trexquant Investment first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 16 quarters since.
  • Trexquant Investment's Intellia Therapeutics position peaked at $10.6M in Q2 2025.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.